+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Non Muscle Invasive Bladder Cancer - Pipeline Insight, 2020

  • ID: 4340489
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 106 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • APIM Therapeutics AS
  • Astellas Pharma Inc.
  • Bavarian Nordic A/S
  • BioCancell Ltd
  • Celgene Corporation
  • Cold Genesys
  • MORE
Non Muscle Invasive Bladder Cancer - Pipeline Insight, 2020 report outlays comprehensive insights of present scenario and growth prospects across Non Muscle Invasive Bladder Cancer. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.

Products covered by Phase
  • Phase III, Phase II, Phase I
  • Pre-clinical & Discovery
  • Inactive (Discontinued and Dormant)
Overview of pipeline development activities for Non Muscle Invasive Bladder Cancer

Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Therapeutic segmentation of products for Non Muscle Invasive Bladder Cancer

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.

Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
  • Provides an overview of therapeutic pipeline activity for Non Muscle Invasive Bladder Cancer across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Non Muscle Invasive Bladder Cancer therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Non Muscle Invasive Bladder Cancer
Reasons to Buy
  • Establish a comprehensive understanding of the current pipeline scenario across Non Muscle Invasive Bladder Cancer to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Non Muscle Invasive Bladder Cancer R&D
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the product and use it for target finding, drug repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Non Muscle Invasive Bladder Cancer to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs


This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • APIM Therapeutics AS
  • Astellas Pharma Inc.
  • Bavarian Nordic A/S
  • BioCancell Ltd
  • Celgene Corporation
  • Cold Genesys
  • MORE
1. Report Introduction

2. Non Muscle Invasive Bladder Cancer - Disease Overview

3. Pipeline Outlook
  • An Overview of Pipeline Products for Non Muscle Invasive Bladder Cancer
4. Comparative Analysis

5. Non Muscle Invasive Bladder Cancer Therapeutic Products in Clinical Stage
5.1 Drug Name : Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
6. Non Muscle Invasive Bladder Cancer Therapeutic Products in Non-clinical Stage
6.1 Drug Name : Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
7. Therapeutic Pipeline Analysis
  • Pipeline Analysis by Route of Administration
  • Pipeline Analysis by Stage and Route of Administration
  • Pipeline Analysis by Molecule Type
  • Pipeline Analysis by Stage and Molecule Type
8. Inactive Pipeline Products
8.1 Drug Description
  • Research and Development Studies
  • Product Development Activities
  • Reason for dormancy/discontinuation
Appendix

Report Methodology

Consulting Services

Disclaimer

About the Publisher

Note: Certain sections of the table of contents would vary according to the availability of information
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Altor BioScience Corporation
  • APIM Therapeutics AS
  • Astellas Pharma Inc.
  • Bavarian Nordic A/S
  • BioCancell Ltd
  • Celgene Corporation
  • Cold Genesys
  • F. Hoffmann-La Roche Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll